SNOA (sonomapharma.com) Net Profit

SNOA (Sonoma Pharmaceuticals) - company brandmark

Sonoma Pharmaceuticals maintains operational independence through its own manufacturing plant in Mexico. The company's net income reflects the dynamics of this process, where -0.00 represents the baseline level of the metric. Success is built upon dermatologist trust and patent purity. Stability in the B2B segment is supported by Microcyn technology and FDA certifications, strengthening the business's position in the skincare sector.

SNOA (Sonoma Pharmaceuticals) Company Net Income history from 07/04/2022 to 11/01/2026

Financial and market metric breakdowns for sonomapharma.com (SNOA)

- price and consensus price forecast:
Stock Quotes Sonoma Pharmaceuticals, Inc.|SNOA - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization Sonoma Pharmaceuticals, Inc.|SNOA - Real Price to Acquire Entire Company
- book capitalization data:
Accounting Value of a Share Sonoma Pharmaceuticals|SNOA - Company Book Value|Market Capitalization to Book Value sonomapharma.com|SNOA - Aggregate Company Assets
- debt and solvency information:
Total Debt to Capital Sonoma Pharmaceuticals|SNOA - Long-Term Debt to Capital|Short-Term Debt to Capital Coefficient Sonoma Pharmaceuticals, Inc.|SNOA - Company Debts|Debt to Book Value Ratio Sonoma Pharmaceuticals, Inc.|SNOA - Company Long-Term Debt|Short-Term Debt Volume Sonoma Pharmaceuticals|Immediate Liquidity sonomapharma.com
- net income and valuation multiples indicators:
SNOA - Company Net Income
Basic company analysis:Sonoma Pharma
Manufactured product of Sonoma Pharma

Global distribution of hypochlorous acid-based dermatological products through pharmacy chains minimizes risks for Sonoma Pharmaceuticals (SNOA), directly impacting the stability of the final financial result. This metric accumulates net operating cash flow minus all expenses, allowing the business's resilience and the growth potential of dividend payments to be assessed through the company's profit dynamics without the distortions caused by quarterly reporting.

Main competitors

Net Income Krystal Biotech Corp.|APGE (Apogee Therapeutics) - Net Profit|Net Profit arcutis.com|Net Income VCEL (Vericel)|ORKA (Oruka Therapeutics, Inc.) - Final Profit|Company Net Income Sanara MedTech SMTI|Net Financial Result DBV Tech (DBVT)|SLSN - Company Net Income|DERM - Net Profit|FBRX: Net Profit|EMPG - Net Financial Result|Company Net Income Sol-Gel|Company Profit AXIL (Revive Pro Care)|Company Net Income Medicus Pharma Ltd. (MDCX)|Net Financial Result verrica.com|Company Net Income Hoth Therapeutics HOTH|Biofrontera, Inc. (BFRI) - Company Net Income|VYNE - Company Net Income|QNRX (Quoin Pharmaceuticals) - Company Profit|Azitra, Inc. (AZTR) - Company Net Income|Company Net Income dermatarx.com (DRMA)|Company Net Income Elevai Labs|Net Income Revance Therapeutics Inc. (RVNC)